New CEO appointed at Nurish.Me

New CEO appointed at Nurish.Me

The Board of Directors wishes to announces David Perez’s resignation as CEO and Chairman of Nurish.Me, effective September 1, 2021. Since co-founding the business in 2018, David has played a critical role in helping to attract top talent and market influencers, while simultaneously leading the business through its nascent stages of development during a tough economic climate.  He leaves the company with two pending lawsuits and a numer of promissory notes due and payable, along with many outstanding creditors. The company faces challenging times ahead, as the incoming CEO will need to navigate the high level of debt and other challenges left to him by the outgoing CEO.

The Board of Directors has ratified that Caesar Kavadoy, be named CEO of Nurish.Me, effective November 1, 2021. Caesar has been involved with Nurish.Me for the past 10 months, first as a direct consultant to the CEO and Board of Directors and then in the interim role as Chief Revenue Officer.  Caesar commenced his transitionay role to CEO alongside David Perez in late June of this year preparing for David's handover of the reigns.

Caesar has a strong history of leading both private and public companies in a variety of capacities to over-achieving their growth and revenue targets.  His consultancy practice which he co-founded in 2009 and will continue to lead, helped companies like Comcast and Lumen (formerly CenturyLink), grow sales and revenue by double-digit sustained growth over 7+ years.  Caesar’s strategy and vision for this business, has already paid dividends in the form of a commercialization plan that was implemented this past April, and has delivered the most profitable year in our company’s history. 

We look forward to Caesar continuing to execute on that strategy, as he develops his team and continues to guide Nurish.Me towards its vision of becoming a pre-eminent player in the health and wellness marketplace.    

“I am honored to serve as Nurish.Me’s next CEO,” said Mr. Kavadoy. “Our Company has an unrivaled, proprietary platform technology that improves the efficacy of our underlying compounds. That technology, working in concert with our robust pipeline of transformational and innovative therapeutics and growing distribution capabilities, will help us to create a much needed disruption in the traditional medicine space.  I look forward to leading this company to become a trusted leader in the health and wellness space and improving shareholder value,  while working tirelessly to provide alternative and complimentary therapeutics to a global community who has been let down by traditional medicine.” 

Mr. Kavadoy will also be appointed as a member of the Company's Board of Directors. Please join me in wishing Caesar the best as he leads Nurish.Me towards a vision that is sure to positively impact our business and the global community for years to come.  

Cautions Concerning Forward-Looking Statements

This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Nurish.Me. Risks and uncertainties include, but are not limited to: risks related to the impact of the COVID-19 global pandemic, such as the scope and duration of the outbreak, government actions and restrictive measures implemented in response, material delays and cancellations of medical procedures, supply chain disruptions and other impacts to the business, or on the Company’s ability to execute business continuity plans, as a result of the COVID-19 pandemic, economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the Company to successfully execute strategic plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health care industry by government agencies.
Any forward-looking statement made in this release speaks only as of the date of this release. Nurish.Me does not undertake to update any forward-looking statement as a result of new information or future events or developments.

Older Post Newer Post